ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 315 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,075,576 | -19.5% | 1,528,678 | +6.9% | 0.04% | -16.0% |
| Q2 2023 | $51,014,019 | +44.8% | 1,430,567 | +3.1% | 0.05% | +38.9% |
| Q1 2023 | $35,231,983 | -35.1% | 1,387,086 | +3.6% | 0.04% | -37.9% |
| Q4 2022 | $54,290,208 | +28.0% | 1,338,516 | +4.3% | 0.06% | +23.4% |
| Q3 2022 | $42,398,000 | -6.2% | 1,282,865 | -0.0% | 0.05% | 0.0% |
| Q2 2022 | $45,177,000 | -23.0% | 1,283,070 | +0.6% | 0.05% | -6.0% |
| Q1 2022 | $58,663,000 | -29.9% | 1,275,556 | +1.0% | 0.05% | +13.6% |
| Q4 2021 | $83,734,000 | -7.4% | 1,262,962 | -12.8% | 0.04% | -12.0% |
| Q3 2021 | $90,431,000 | -21.6% | 1,448,514 | +4.0% | 0.05% | -18.0% |
| Q2 2021 | $115,301,000 | +16.7% | 1,392,194 | -6.5% | 0.06% | +19.6% |
| Q1 2021 | $98,783,000 | -15.5% | 1,489,716 | -2.2% | 0.05% | -10.5% |
| Q4 2020 | $116,910,000 | +85.3% | 1,523,647 | +4.0% | 0.06% | +46.2% |
| Q3 2020 | $63,093,000 | +6.7% | 1,465,242 | +7.0% | 0.04% | -7.1% |
| Q2 2020 | $59,117,000 | +153.4% | 1,368,767 | +68.8% | 0.04% | +110.0% |
| Q1 2020 | $23,330,000 | -3.5% | 810,892 | +112.7% | 0.02% | +11.1% |
| Q4 2019 | $24,182,000 | +729.6% | 381,224 | +268.4% | 0.02% | +800.0% |
| Q3 2019 | $2,915,000 | +32.1% | 103,492 | +24.3% | 0.00% | 0.0% |
| Q2 2019 | $2,206,000 | -59.8% | 83,233 | -72.2% | 0.00% | -60.0% |
| Q1 2019 | $5,492,000 | +28.5% | 299,265 | -13.0% | 0.01% | +25.0% |
| Q4 2018 | $4,275,000 | +169.5% | 344,163 | +316.0% | 0.00% | +300.0% |
| Q3 2018 | $1,586,000 | +62.2% | 82,739 | +15.1% | 0.00% | 0.0% |
| Q2 2018 | $978,000 | +629.9% | 71,896 | +97.0% | 0.00% | – |
| Q4 2017 | $134,000 | +16.5% | 36,489 | -41.0% | 0.00% | – |
| Q1 2017 | $115,000 | -30.3% | 61,803 | -41.7% | 0.00% | – |
| Q4 2016 | $165,000 | -86.1% | 105,984 | -34.4% | 0.00% | -100.0% |
| Q3 2016 | $1,190,000 | +50.6% | 161,640 | +8.9% | 0.00% | 0.0% |
| Q2 2016 | $790,000 | – | 148,481 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |